VYNE Therapeutics Inc. (VYNE) News

VYNE Therapeutics Inc. (VYNE): $0.57

0.02 (+3.76%)

POWR Rating

Component Grades













Add VYNE to Watchlist
Sign Up

Industry: Biotech


of 450

in industry

Filter VYNE News Items

VYNE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VYNE News Highlights

  • VYNE's 30 day story count now stands at 4.
  • Over the past 16 days, the trend for VYNE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about VYNE are FOLD, CMAX and GEL.

Latest VYNE News From Around the Web

Below are the latest news stories about VYNE Therapeutics Inc that investors may wish to consider to help them evaluate VYNE as an investment opportunity.

VYNE Therapeutics reports initial data from phase 1b/2a study of FMX114 for eczema

VYNE Therapeutics (VYNE -4.1%) completed the phase 1b portion of a phase 1b/2a trial evaluating topical FMX114 to treat mild-to-moderate atopic dermatitis (AD), also known as the skin condition eczema. FMX114 is VYNE’s proprietary investigational combination gel formulation of tofacitinib and fingolimod. The phase 1b portion included four patients with mild to moderate...

Seeking Alpha | January 19, 2022

VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents Mean Cmax of tofacitinib 50-fold and 1500-fold lower at Day 1 and 14 of study compared to the lowest commercially available oral alternative Findings from Phase 1b safety portion of study support trial continuation Topline Phase 2a results expected in Q1 2022 BRIDGEWATER, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics I

Yahoo | January 19, 2022

VYNE Therapeutics Divests Topical Minocycline Assets

Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic plan; proceeds will be used to fund development of Company’s immuno-inflammatory pipeline BRIDGEWATER, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has sold its Molecule Stabilizing Technology (MST™) franchise, including AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline)

Yahoo | January 13, 2022

VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event

BRIDGEWATER, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that management will participate in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022. About VYNE Therapeutics Inc. VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. T

Yahoo | January 3, 2022

Do Options Traders Know Something About VYNE Therapeutics (VYNE) Stock We Don't?

Investors need to pay close attention to for VYNE Therapeutics (VYNE) stock based on the movements in the options market lately.

Yahoo | December 13, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning, investor!

William White on InvestorPlace | December 10, 2021

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), VYNE Therapeutics (VYNE) and Stoke Therapeutics (STOK)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Summit Therapeutics (SMMT – Research Report), VYNE Therapeutics (VYNE – Research Report) and Stoke Therapeutics (STOK – Research Report). Summit Therapeutics (SMMT) In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Summit Therapeutics. The company's shares closed last Friday at $5.00, close to its 52-week low of $4.55. According to TipRanks.com, Arce is a 4-star analyst with an average return of -8.2% and a 28.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Carrie Williams on TipRanks | December 6, 2021

GCP Stock: The Big Buyout News That Has GCP Applied Technologies Bounding Higher Today

GCP Applied Technologies (GCP) stock is rising higher on Monday thanks to a massive $2.3 billion buyout deal from Saint-Gobain.

William White on InvestorPlace | December 6, 2021

Restaurant Stocks: What’s Going on With TACO, DIN, CAKE, MCD, BJRI and FRGI Today?

Restaurant stocks are on the move Monday and we're diving into today's news to give traders all the details on why that's happening.

William White on InvestorPlace | December 6, 2021

VYNE Stock Price Predictions: Why One Analyst Sees VYNE Therapeutics Going to $7

VYNE Therapeutics (VYNE) stock price predictions are heating up on Monday with one analyst setting a high goal for the company to reach.

William White on InvestorPlace | December 6, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6828 seconds.